NCT06948318View on ClinicalTrials.gov

A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

PHASE3RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

July 29, 2029

Study Completion Date

July 29, 2029

Conditions

Immune Thrombocytopenic Purpura (ITP)

Interventions

DRUG

Mezagitamab

Mezagitamab injection administered SC.

Trial Locations (1)

201508

RECRUITING

Jinshan Hospital of Fudan University, Shanghai

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY